CSL.AX - CSL Limited

ASX - ASX Delayed price. Currency in AUD

CSL Limited

45 Poplar Road
Parkville, VIC 3052
61 3 9389 1911

Full-time employees25,031

Key executives

NameTitlePayExercisedYear born
Mr. Paul R. PerreaultMD, CEO & Exec. Director3.72MN/A1957
Mr. David Mark Lamont ACA, BComChief Financial Officer1.68MN/A1966
Dr. Robert Andrew CuthbertsonChief Scientific Officer, Director of R&D and Director1.37MN/A1955
Mr. Gregory Boss BS(Hons), J.D.Exec. VP of Legal & Group Gen. Counsel1.1MN/A1961
Ms. Elizabeth WalkerExec. VP & Chief HR Officer796.65kN/A1970
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Corporate governance

CSL Limited’s ISS governance QualityScore as of 6 December 2019 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 1; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.